8-K: AVITA Medical Announces Successful Australian Equity Raise (Exhibit 99.1)

Rhea-AI Filing Summary

AVITA Medical, Inc. filed a Current Report on Form 8-K dated August 12, 2025, reporting that the company issued a press release announcing the successful completion of an equity raise in Australia. The filing states the press release is attached as Exhibit 99.1 and clarifies that the information furnished, including the exhibit, is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The 8-K is signed by Chief Financial Officer David O'Toole. The company's common stock trades under the symbol RCEL on Nasdaq.

Positive

• Successful completion of an equity raise in Australia is explicitly announced in the attached press release (Exhibit 99.1).
• Timely disclosure via Form 8-K indicates the company is informing the market of a material corporate event.

Negative

• No disclosure of amount, pricing, or investor identity in the 8-K, preventing assessment of financial impact.
• Exhibit is furnished, not filed, which limits incorporation into future filings under the Exchange Act.

Insights

Financial Analyst

TL;DR: The company announced completion of an Australian equity raise, but the 8-K provides no financial terms or amounts.

The filing confirms a press release announcing a completed equity raise in Australia and attaches that release as Exhibit 99.1. Absent in the 8-K are key financing details such as proceeds raised, share issuance terms, investor identity, and expected use of proceeds, so the filing does not allow quantification of the transaction's impact on capital structure or liquidity. The statement that the exhibit is "furnished" rather than "filed" limits legal incorporation into other filings.

Corporate Governance Expert

TL;DR: Material event disclosed but disclosure is limited; governance implications depend on undisclosed transaction specifics.

The 8-K meets disclosure by notifying investors that a press release announces a completed equity raise in Australia and by attaching the release as Exhibit 99.1. The document includes the standard proviso that the information is furnished, not filed. Because the 8-K lacks details on terms, dilutive effect, or approvals, governance stakeholders cannot assess board authorization, related-party considerations, or compliance with prior financing authorizations solely from this filing.

false000176230300017623032025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

AVITA Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39059	85-1021707
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
28159 Avenue Stanford Suite 220
Valencia, California				91355
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 661 367-9170

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		RCEL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On August 12, 2025, the Company issued a press release announcing the successful completion of an equity raise in Australia. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information furnished in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description of Exhibit
99.1	Press release, dated August 12, 2025, issued by AVITA Medical, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AVITA Medical, Inc
Date:	August 12, 2025	By:	/s/ David O'Toole
			David O'Toole Chief Financial Officer